Healthcare Dec 31, 2021 05:55 PM (GMT+8) · EqualOcean
In December 31st, Dahl Sealy, a CDK4/6 inhibitor of Heng Rui medicine, was approved to be listed. Combined with fluticasone group, it was suitable for patients with recurrent or metastatic breast cancer who had been progresses in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) before receiving endocrine therapy. Darcy is an oral selective small molecule CDK 4 / 6 inhibitor developed by Hengrui medicine, which is a class 1 new drug. Shr6390 can selectively inhibit the activity of CDK4 / 6 kinase, block the CDK4 / 6-rb signal pathway, induce the arrest of G1 phase and selectively inhibit the proliferation of Rb overexpressing tumor cells, so as to achieve the effect of anti-tumor.
Related companies: